CLARIANT ADR 1/SF 4 (CLRS) - Net Assets
Based on the latest financial reports, CLARIANT ADR 1/SF 4 (CLRS) has net assets worth €2.18 Billion EUR (≈ $2.55 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.87 Billion ≈ $6.86 Billion USD) and total liabilities (€3.69 Billion ≈ $4.31 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CLARIANT ADR 1/SF 4 assets under control for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.18 Billion |
| % of Total Assets | 37.17% |
| Annual Growth Rate | -3.76% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 11.55 |
CLARIANT ADR 1/SF 4 - Net Assets Trend (2021–2025)
This chart illustrates how CLARIANT ADR 1/SF 4's net assets have evolved over time, based on quarterly financial data. For live valuation and market cap data, see CLRS market cap.
Annual Net Assets for CLARIANT ADR 1/SF 4 (2021–2025)
The table below shows the annual net assets of CLARIANT ADR 1/SF 4 from 2021 to 2025. Explore CLARIANT ADR 1/SF 4 cash flow conversion to assess how effectively this company generates cash.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €2.18 Billion ≈ $2.55 Billion |
-13.00% |
| 2024-12-31 | €2.51 Billion ≈ $2.93 Billion |
+15.05% |
| 2023-12-31 | €2.18 Billion ≈ $2.55 Billion |
-13.25% |
| 2022-12-31 | €2.51 Billion ≈ $2.94 Billion |
-1.22% |
| 2021-12-31 | €2.54 Billion ≈ $2.97 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CLARIANT ADR 1/SF 4's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.91 Billion | 143.58% |
| Total Equity | €2.02 Billion | 100.00% |
CLARIANT ADR 1/SF 4 Competitors by Market Cap
The table below lists competitors of CLARIANT ADR 1/SF 4 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Almirall S.A.
MC:ALM
|
$2.63 Billion |
|
Atlanta Braves Holdings, Inc. Series C Common Stock
NASDAQ:BATRK
|
$2.63 Billion |
|
Shanghai Zhenhua Heavy Industries Co Ltd A
SHG:600320
|
$2.63 Billion |
|
Hawaiian Electric Industries Inc
NYSE:HE
|
$2.64 Billion |
|
Plug Power Inc
NASDAQ:PLUG
|
$2.63 Billion |
|
Dongguan Yiheda Automation Co. Ltd.
SHE:301029
|
$2.63 Billion |
|
Double Medical Technology Inc
SHE:002901
|
$2.63 Billion |
|
Shyam Metalics and Energy Limited
NSE:SHYAMMETL
|
$2.63 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CLARIANT ADR 1/SF 4's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,335,000,000 to 2,024,000,000, a change of -311,000,000 (-13.3%).
- Net loss of 75,000,000 reduced equity.
- Dividend payments of 138,000,000 reduced retained earnings.
- Other factors decreased equity by 98,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-75.00 Million | -3.71% |
| Dividends Paid | €138.00 Million | -6.82% |
| Other Changes | €-98.00 Million | -4.84% |
| Total Change | €- | -13.32% |
Book Value vs Market Value Analysis
This analysis compares CLARIANT ADR 1/SF 4's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.54x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.32x to 1.54x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €7.16 | €9.45 | x |
| 2022-12-31 | €7.12 | €9.45 | x |
| 2023-12-31 | €6.14 | €9.45 | x |
| 2024-12-31 | €7.11 | €9.45 | x |
| 2025-12-31 | €6.15 | €9.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CLARIANT ADR 1/SF 4 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.92%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 2.90x
- Recent ROE (-3.71%) is below the historical average (6.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 14.59% | 7.87% | 0.62x | 2.98x | €108.20 Million |
| 2022 | 3.59% | 1.62% | 0.84x | 2.64x | €-150.10 Million |
| 2023 | 6.64% | 3.06% | 0.82x | 2.65x | €-67.80 Million |
| 2024 | 10.45% | 5.88% | 0.66x | 2.68x | €10.50 Million |
| 2025 | -3.71% | -1.92% | 0.67x | 2.90x | €-277.40 Million |
Industry Comparison
This section compares CLARIANT ADR 1/SF 4's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $3,039,854,957
- Average return on equity (ROE) among peers: -28.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CLARIANT ADR 1/SF 4 (CLRS) | €2.18 Billion | 14.59% | 1.69x | $2.63 Billion |
| GRAPHENE MANUFACT.GROUP (0GF) | $8.54 Million | -86.66% | 0.78x | $152.93 Million |
| Orion Engineered Carbons SA (0OE) | $474.90 Million | 9.31% | 2.91x | $318.41 Million |
| H&R GmbH & Co. KGaA (2HRA) | $471.16 Million | 9.06% | 1.04x | $183.88 Million |
| Dotz Nano Ltd (57N) | $421.99K | -248.22% | 1.80x | $3.81 Million |
| EXPLOS. PROD. CHIM.EO 31 (9Z50) | $144.93 Million | 14.73% | 2.07x | $536.15 Million |
| Altech Chemicals Ltd (A3Y) | $88.93 Million | 2.62% | 0.01x | $27.76 Million |
| AlzChem Group AG (ACT) | $68.66 Million | 28.68% | 4.16x | $1.83 Billion |
| AIR LIQUIDE ADR 1/5/EO 11 (AILA) | $24.57 Billion | 11.23% | 1.02x | $103.86 Billion |
| AKZO NOBEL SPONS.ADRS 1/3 (AKUP) | $4.55 Billion | 9.72% | 2.20x | $8.57 Billion |
| BRAIN Biotech AG (BNN) | $23.01 Million | -35.97% | 2.08x | $51.56 Million |
About CLARIANT ADR 1/SF 4
Clariant AG develops, manufactures, distributes, and sells specialty chemicals in Switzerland, Europe, the Middle East, Africa, the United States, and the Asia Pacific. It operates through Care Chemicals, Catalysts, and Adsorbents & Additives segments. The Care Chemicals segment offers personal and home care, crop solutions, industrial applications, base chemicals, oil services, and mining soluti… Read more